Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
This study has been completed.
Study NCT00202774   Information provided by Spanish Cooperative Group for Gastrointestinal Tumour Therapy

First Received on September 12, 2005.   Last Updated on February 19, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Colorectal Cancer
Additional conditions recognized in this trial
Colorectal Neoplasms
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Additional drug interventions recognized in this trial
Capecitabine
Fluorouracil
Oxaliplatin
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Spanish Cooperative Group for Gastrointestinal Tumour Therapy


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services